文献速递银屑病与炎症性皮肤病

乌司奴单抗治疗与中重度银屑病患者全身及血管炎症降低相关:基于18F-氟脱氧葡萄糖PET/CT的可行性研究

Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: Feasibility study using 18F-fluorodeoxyglucose PET/CT.
PubMed 文献 · J Am Acad Dermatol · 2018-03-17

本研究为可行性研究,中重度银屑病患者接受乌司奴单抗治疗,在达到银屑病面积和严重程度指数75后复查18F-FDG PET/CT,结果显示肝脏、脾脏及主动脉5个部位的标准化摄取值降低(P < .05)。

要点

  • 中重度银屑病患者达到PASI 75后,肝脏、脾脏及主动脉5个部位标准化摄取值降低(P < .05)。
  • 研究仅显示替代标志物变化,未提供心血管事件或代谢综合征的结局数据。
  • 结论限于有限的韩国人群。

核心结论

  • 乌司奴单抗治疗与银屑病患者代谢综合征及心血管疾病相关的全身和血管炎症降低显著相关。

研究设计与样本

  • 可行性研究,银屑病患者与健康对照基线行18F-FDG PET/CT,中重度银屑病患者接受乌司奴单抗治疗并在达到PASI 75后再次行18F-FDG PET/CT。

主要发现

  • 达到PASI 75后,肝脏、脾脏及主动脉5个部位的标准化摄取值降低(P < .05)。

局限性

  • 研究未提供心血管事件或代谢综合征的结局数据。
  • 仅在有限的韩国人群中显示替代标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Evidence suggests that psoriasis might be associated with metabolic syndrome and an increased risk for cardiovascular disease. OBJECTIVE: To determine whether ustekinumab reduces systemic and vascular inflammation associated with metabolic syndrome and cardiovascular disease, measured using 18F-fluorodeoxyglucose positron emission tomography-computed tomography (18F-FDG PET/CT). METHODS: Patients with psoriasis and healthy controls underwent baseline 18F-FDG PET/CT imaging. Patients with moderate-to-severe psoriasis were treated with ustekinumab and underwent 18F-FDG PET/CT again after a Psoriasis Area and Severity Index of 75 was achieved. RESULTS: After a Psoriasis Area and Severity Index of 75 was achieved with ustekinumab treatment, standardized uptake values were reduced in the liver, spleen, and 5 parts of the aorta (P < .05). LIMITATIONS: Our study does not provide outcome data concerning cardiovascular events or metabolic syndrome; it only shows surrogate markers in a limited (Korean) population. CONCLUSION: Ustekinumab treatment was significantly associated with decreased systemic and vascular inflammation related to metabolic syndrome and cardiovascular disease among patients with psoriasis.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Kim BS, Lee WK, Pak K, et al. Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate-to-severe psoriasis: Feasibility study using 18F-fluorodeoxyglucose PET/CT. J Am Acad Dermatol. 2018. PMID: 29559399. doi:10.1016/j.jaad.2018.03.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。